Clinical Trial Supplies Market: Growth, Size, Share, and Trends

The clinical trial supplies market is projected to reach USD 6.3 billion by 2028 from USD 3.9 billion in 2023, at a CAGR of 9.9 % during the forecast period. The growth of the clinical trial supplies market is driven by increasing trial complexity, particularly with the rise of biologics, biosimilars, and advanced therapies. Heightened regulatory scrutiny and the need for robust temperature-controlled logistics for sensitive materials, such as cell and gene therapies, are driving the adoption of advanced technologies. Furthermore, increasing industrial collaborations for drug development is likely to give momentum to clinical trials supplies market growth.

Clinical Trial Supplies Market Size, Dynamics & Ecosystem

To know about the assumptions considered for the study, Request for Free Sample Report

Global Clinical Trial Supplies Market Dynamics

Drivers: Increasing the number of registered clinical trials

The growing number of registered clinical trials is a key driver of the clinical trial supplies market. As research into innovative therapeutics expands, the demand for specialized supplies, including comparator drugs, biological samples, and ancillary equipment, has surged. For instance, clinical.gov in 2024 number of registered studies was around 43,680 in a year with 10.0% growth compared to 2023. As of January 2025, around 1,768 clinical trials studies have been registered. The rise in trials targeting complex diseases like cancer, neurological disorders, and rare diseases further intensifies the need for temperature-controlled logistics and advanced packaging solutions, specifically for biologics and cell-based therapies.

The increasing number of registered clinical trials is directly driving market growth by raising demand for advanced packaging, labeling, and delivery solutions. With more trials targeting complex biologics and decentralized models, companies must invest in temperature-controlled packaging, multi-language labeling systems, and direct-to-patient delivery methods to ensure compliance and drug integrity. These needs are creating opportunities for providers of specialized supplies and logistics services.

Restraints: High Cost of clinical trials/drug development

The substantial costs associated with clinical trials represent a critical impediment to the growth of the clinical trial supplies market. The expenses involved encompass trial design, patient recruitment, site management, and logistics, often reaching millions of dollars per trial phase. According to industry estimates, the average cost to bring a new drug to market exceeds ~ USD 1 billion, with a substantial portion allocated to clinical trial phases. The patient recruitment alone constituting up to 40% of total expenses due to the challenges in identifying, enrolling, and retaining suitable participants. Logistics and supply chain complexities, especially for temperature-sensitive biologics, add another layer of expense. For instance, the global distribution of mRNA-based COVID-19 vaccines during clinical trials, which required specialized cold chain solutions, significantly increasing costs.

Opportunities: Growing Decentralized Clinical Trials (DCTs)

The growing adoption of Decentralized Clinical Trials (DCTs) is revolutionizing the clinical trial landscape, creating lucrative growth opportunities in the clinical trial supplies market. DCTs leverage telemedicine, remote monitoring, and digital platforms to bring trials closer to patients, eliminating the need for frequent site visits. This paradigm shift increases the demand for direct-to-patient (DTP) supply models, home healthcare services, and robust logistics networks.

The growing adoption of DCTs has significantly increased the need for advanced supply chain solutions, including real-time tracking technologies and temperature-controlled packaging, to maintain product integrity. Logistics providers that can deliver these capabilities are well-positioned for growth as sponsors and contract research organizations (CROs) emphasize flexibility and a patient-centric approach.

Moreover, DCTs are enhancing trial accessibility for diverse and underserved populations, adding complexity and scale to supply chain operations. Businesses that invest in robust infrastructure, digital technologies, and patient-focused logistics solutions are strategically placed to seize opportunities in this transformative market shift.

Challenges: Supply Chain Complexity

Supply chain complexity is a critical challenge impacting the growth of the clinical trial supplies market. The globalization of clinical trials requires seamless coordination across multiple countries, each with unique regulatory requirements, customs protocols, and logistical hurdles. The need for precise temperature-controlled storage and transportation for biologics and other sensitive products adds to the complexity. Unpredictable patient enrolment and shifting trial designs further complicate demand forecasting, increasing risks of overproduction, stockouts, and waste. Additionally, geopolitical disruptions and supply chain bottlenecks can delay deliveries and compromise trial timelines.

Global Clinical trial supplies Ecosystem Analysis

The clinical trial supplies market operates within a complex ecosystem with a wide array of stakeholders, each playing a crucial role in developing and adopting clinical trial supplies. This ecosystem encompasses service providers, end users, and regulatory bodies. It evaluates their interactions, dependencies, and contributions within the industry, providing insights into the broader market dynamics and trends. Prominent companies in the market include companies operating for several years that possess diversified service portfolios, strong global sales, and marketing networks.

Logistics and distribution segment dominated the clinical trial supplies market in 2022.

The clinical trial supplies market by services is segmented into logistics & distribution, packaging, labelling & binding, storage & retention, manufacturing, comparator sourcing and other services. The logistics & distribution dominated the market in 2022. Logistics and distribution play a critical role in ensuring the timely and compliant delivery of investigational products. Key factors driving their dominance include the complexity of supply chain management, the need to comply with regulatory standards (such as GDP), and the increasing intricacy of trials, particularly those involving decentralized and advanced therapies, which require specialized logistics services.

Small molecule drugs segment dominated the type of segment in clinical trial supplies market in 2022.

The clinical trial supplies market is broadly segmented into biologic drugs, small molecule drugs, and medical devices. The small molecule drugs segment dominated the market in 2022 and anticipated grow at significant rate in coming years. The clinical trial supplies market for small molecules is driven by the consistent development of conventional pharmaceuticals and generics.

Oncology segment is anticipated to grow at significant CAGR during the forecast period.

The clinical trial supplies market is segmented into oncology, infectious diseases, neurology, metabolic disorders, immunology, cardiology, genetic and rare diseases, and other therapeutic areas (respiratory disorders, dermatological disorders, ENT diseases, and nephrology). The areas of oncology, cardiology, and infectious diseases are expected to see the most significant growth. Oncology is the largest therapeutic area in the clinical trial supplies market, owing to high prevalence of cancer, the increasing focus on targeted therapies and immunotherapy, and the complex clinical trial designs required for these therapies.

The pharmaceutical and biotechnology companies segment accounted for the largest share in 2022.

Based on end users, the clinical trial supplies market is further segmented into, pharmaceutical & biotechnology companies, contract research organizations (CROs), and medical device companies. In 2022, the pharmaceutical and biotechnology companies accounted for the largest share of this market. This dominance is driven by their extensive involvement in drug and therapy development, leading to a high demand for clinical trial supplies. The rise of biologics, biosimilars, and advanced therapies like gene and cell therapies has further expanded the need for specialized clinical trial supplies, particularly for temperature-sensitive and highly regulated products.

US dominated North America clinical trial supplies market in 2022.

The market is segmented into six major regions namely, North America, Europe, the Asia Pacific, Latin America, Middle East and Africa. In 2022, North America dominated the clinical trial supplies market and anticipated grow at significant CAGR during the forecast period of 2023-2028. US dominated North America clinical trial supplies market, driven by presence of robust pharmaceutical and biopharmaceutical companies, advanced healthcare infrastructure, and extensive clinical trials activity. For instance, as per WHO US accounts for more than 20% of the total clinical trials registered across the globe. Europe accounted for second largest share in 2022, some of the factor uplifting the market are companies are increasingly outsourcing clinical trial logistics and supply chain management to specialized service providers in Europe. Asia Pacific witnessing highest growth rate owing to an increase in clinical trials due to its large, diverse patient pool and the growing prevalence of chronic and rare diseases. Furthermore, rapid expansion of the pharmaceutical and biotechnology industries in APAC is driving the need for robust clinical trial infrastructure.

Over the course of the forecast, Asia Pacific is expected to expand somewhat quickly. One of the elements responsible for the expansion is the increase in clinical trials conducted by biotechnology and pharmaceutical businesses. Moreover, the availability of a sizable and varied patient population, less running costs than in industrialised countries, and strong legislative backing for clinical research is probably going to drive regional market expansion.

Clinical Trial Supplies Market Segmentation & Geographical Spread

To know about the assumptions considered for the study, download the pdf brochure

Key Market Players

Key players in the market include Thermo Fisher Scientific Inc. (US), Marken (US), Catalent, Inc. (US), Eurofins Scientific (France), and PRA Health Sciences (US), Parexel International (MA) Corporation (US), Biocair (UK), AlmacGroup (UK), Piramal Pharma Solutions (India), Sharp Services, LLC (US), PCI Pharma Services (US), Nuvisan (Germany), Lonza Group (Switzerland), OCT Group LLC (US), Corex Logistic Limited (Ireland), Acnos Pharma GMBH (Germany), Clinical Service International (UK), Klifo (Denmark), Clinigen Limited (UK), Ancillare LP (US), N-Side (Europe), ADAllen pharma (UK), Durbin (UK), Recipharm AB (Sweden), IPS Pharma (UK).

Scope of the Clinical Trial Supplies Industry:

This report categorizes the clinical trial supplies market to forecast revenue and analyze trends in each of the following submarkets:

By Service

• Logistics & Distribution
• Storage & Retention
• Packaging, Labelling & Blinding
• Manufacturing
• Comparator Sourcing
• Other Services (Solutions and Ancillary supplies)

By Phase

• Phase I
• Phase II
• Phase III
• Phase IV
• BA/BE Studies

By Type

• Small-Molecules
• Biologic Drugs
• Medical Devices

By Therapeutic Area

• Oncology
• Infectious Diseases
• Neurology
• Metabolic Disorders
• Immunology
• Cardiology
• Genetic Diseases
• Other Therapeutic Areas (Respiratory diseases, dermatological conditions, rare diseases, ENT diseases, and nephrology)

By End User

• Pharmaceutical and Biotechnology Companies
• Contract Research Organisations (CRO's)
• Medical Device Companies

By Region

• North America
  • US
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Switzerland
  • Netherlands
  • Rest of Europe (ROE)
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Singapore
  • Rest of Asia Pacific
• Latin America
  • Mexico
  • Brazil
  • RoLATAM
• Middle East
• Africa

Recent Developments Clinical Trial Supplies Industry

• In July 2023, Thermo Fisher Scientific Inc. (US) and national minority quality forum (NMQF) entered into collaboration with the), which is a non-profit organization dedicated to research and education. This collaboration facilitated through NMQF’s Alliance for Representative Clinical Trials (ARC) in order to increase the inclusion of historically underprivileged patient groups in clinical research.
• In April 2023, Almac Group (UK), introduced the IXRS3 Partnership Network, designed to expedite the creation and deployment of advanced eClinical solutions for biopharmaceutical sponsors.
• In March 2023, Icon Plc (Ireland) and LEO Pharma (Denmark) entered into a strategic partnership in order to enhance LEO Pharma's clinical trial operations, focusing on patient-centricity, cost-efficiency and to strengthen LEO Pharma.
• In August 2022, Marken (US) acquired Bomi Group (Italy) to boost cold chain capacity in key European and Latin American countries and therefore help the expansion in healthcare logistics by strengthening the company's worldwide presence.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst